Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Biologically active molecules that reduce polyglutamine aggregation and toxicity.

Urvee A Desai1, Judit Pallos, Aye Aye K Ma

  • 1Department of Neurology and Cellular and Molecular Pharmacology, San Francisco, CA 94143-2280, USA.

Human Molecular Genetics
|May 25, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Emerging roles of ferroptosis in modulating the immune landscape of glial tumours.

Nature cell biology·2026
Same author

MiR-940 Suppresses Ferroptosis by Controlling Expression of Key Regulatory Genes.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026
Same author

GPX4 regulates lipid peroxidation and ferroptosis of stored red blood cells.

Blood. Red cells & iron·2026
Same author

Dissecting Polypharmacology in Phenotypic Screening to Resolve Ferroptotic and Necrotic Cell-Death Mechanisms.

ACS medicinal chemistry letters·2026
Same author

When Pathways Converge: Iron, Lipid Peroxidation, and α-Synuclein in Ferroptosis-Driven Dopaminergic Neurodegeneration.

Journal of neurochemistry·2026
Same author

Ferroptosis as an approach to leverage cancer metabolism.

Trends in cell biology·2026

Researchers identified small molecules that inhibit protein aggregation in polyglutamine diseases. These compounds show promise for developing new therapies for neurodegenerative conditions like Huntington disease.

Area of Science:

  • Neuroscience
  • Molecular Biology
  • Pharmacology

Background:

  • Polyglutamine expansion in proteins causes neurodegeneration in inherited disorders.
  • Protein aggregation, driven by polyglutamine tracts, is a key factor in cellular toxicity and neurodegeneration.

Purpose of the Study:

  • To identify inhibitors of androgen receptor (AR) aggregation using a FRET-based assay.
  • To screen libraries of biologically active small molecules for compounds that reduce polyglutamine protein aggregation.

Main Methods:

  • Utilized an intracellular FRET-based assay to screen three small molecule libraries for AR aggregation inhibitors.
  • Tested identified compounds in a PC-12 cell model and a Drosophila model of Huntington disease (Htt) exon 1 aggregation and neurodegeneration.

Related Experiment Videos

Main Results:

  • Ten compounds reduced AR aggregation in the primary screen.
  • Nine of ten compounds reduced aggregation in a PC-12 model; five compounds partially rescued neurodegeneration in a Drosophila model.
  • Three of the effective compounds in Drosophila are FDA-approved drugs.

Conclusions:

  • The identified compounds offer potential therapeutic leads for polyglutamine diseases.
  • The FRET-based screening assay demonstrates high predictive value and utility for future screens of inhibitors.